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Abstract 
Background: Rubella infections in susceptible women during early pregnancy often results in congenital rubella 
syndrome (CRS). World Health Organisation (WHO) recommends that countries without vaccination programmes to 
assess the burden of rubella infection and CRS. However; in many African countries there is limited data on epidemi-
ology of rubella infection and CRS. This review was undertaken to assess the serological markers and genotypes of 
rubella virus on the African continent in order to ascertain the gap for future research.
Findings: A systematic search of original literatures from different electronic databases using search terms such 
as ‘rubella’ plus individual African countries such as ‘Tanzania’, ‘Kenya’, ‘Nigeria’ etc. and different populations such as 
‘children’, ‘pregnant women’ etc. in different combinations was performed. Articles from countries with rubella vac-
cination programmes, outbreak data and case reports were excluded. Data were entered in a Microsoft Excel sheet 
and analyzed. A total of 44 articles from 17 African countries published between 2002 and 2014 were retrieved; of 
which 36 were eligible and included in this review. Of all population tested, the natural immunity of rubella was 
found to range from 52.9 to 97.9 %. In these countries, the prevalence of susceptible pregnant women ranged from 
2.1 to 47.1 %. Rubella natural immunity was significantly higher among pregnant women than in general population 
(P < 0.001). Acute rubella infection was observed to be as low as 0.3 % among pregnant women to 45.1 % among 
children. All studies did not ascertain the age-specific prevalence, thus it was difficult to calculate the rate of infec-
tion with increase in age. Only two articles were found to report on rubella genotypes. Of 15 strains genotyped; three 
rubella virus genotypes were found to circulate in four African countries.
Conclusion: Despite variations in serological assays, the seroprevalence of IgG rubella antibodies in Africa is high 
with a substantial number of women of childbearing age being susceptible to rubella infection. Standardized sero-
epidemiological data in various age groups as well as CRS data are important to implement cost-effective vaccination 
campaigns and control strategies.
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Findings
Background
Rubella or ‘German measles’ is a mild viral disease caused 
by the rubella virus. Rubella is RNA virus in the family 
Togaviridae and is transmitted by droplets, direct contact 
or vertically from pregnant woman to the fetus [1]. The 
virus is worldwide distributed and is of public health 
concern due to its teratogenic effects. Infections in sus-
ceptible women during early pregnancy may results into 
multiple birth defects known as congenital rubella syn-
drome (CRS). Each year more than 100,000 children 
particularly in developing countries are born with CRS 
[2–4]. The CRS is mainly characterized by a triad of con-
genital heart diseases, congenital cataracts, and deafness; 
and many other defects [5].
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Rubella is among many vaccine-preventable diseases; 
the main goal of vaccination is to reduce the incidence 
of rubella virus infection and CRS. In countries with 
vaccination programme especially in developed coun-
tries, the number of CRS cases have been markedly 
reduced [6, 7]. Despite the decrease in number of CRS 
cases worldwide, rubella remains a public health prob-
lem in Africa [3, 4]. Lack of vaccination programme in 
children contributes to increase in CRS cases because 
children usually harbour and spread the infection in 
community including susceptible pregnant women [8].
Despite high prevalence of congenital malformations 
in Africa [9, 10] few countries have introduced rubella 
vaccination in their national immunization programs 
to reduce incidence of acute rubella infections and 
CRS cases. World Health Organization (WHO) recom-
mends that countries without national rubella vaccina-
tion programmes should assess the burden of rubella 
and CRS through sero-epidemiological surveys that may 
be implemented in parallel with measles surveillance 
[11]. However, there is limited data on epidemiology of 
rubella and CRS in Africa. The main objective of this 
review was to determine the gap of literatures based on 
WHO recommendations and accuracy of data to be used 
as baseline before rubella vaccination is introduced.
Methods
Following PRISMA checklist (Additional file  1) system-
atic review was done. Systematic search for literature/
original articles published in english focusing on rubella 
sero-epidemiology in Africa was performed using online 
database (PubMed/Medline, Embase, Popline, Global 
Health, Google Scholar and Web of Knowledge). The 
search was performed using terms; ‘rubella’ plus individ-
ual African countries like Tanzania, Kenya, Liberia, Nige-
ria etc., seroprevalence, pregnant women, adolescents, 
children in different combinations.
New links displayed in each abstract were followed 
and more abstracts were retrieved. Abstracts were care-
fully reviewed to exclude all articles published before 
2002. Bibliographies of the retrieved articles were care-
fully reviewed and relevant articles published within 
the time frame were also retrieved. The search revealed 
44 articles from 17 countries published between 2002 
and 2014. Further analysis excluded; 2 case reports, 4 
articles with outbreak data (WHO surveillance) and 2 
articles from countries with national rubella vaccina-




Fig. 1 Flow chart showing articles and exclusion criteria
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Data extraction and analysis
Eligible articles were reviewed independently by two 
authors. The data were recorded in excel sheet contain-
ing the subtitles such as region (country), study design, 
study population, age range, technique used, cut-off 
points, Immunoglobulin M (IgM) and Immunoglobulin 
G (IgG) seroprevalence, number of samples tested nega-
tive, whether the study was conducted in rural or urban 
settings, season, strain of circulating virus (if any), author 
and date of publication. Data were manually analysed to 
obtain proportions of natural immunity. Proportion test 
using STATA version 11 was done to establish statistical 
differences.
Results
Of 36 articles reviewed, 20 (55.5  %) were conducted 
between 2007 and 2014. In these articles; population 
tested included pregnant women aged between 15 and 
50  years, children aged from 0 to 18  years and gen-
eral adult population aged between 19 and 62  years. 
The rubella natural immunity in these countries ranged 
from 52.9  % among pregnant women in Benin Nigeria 
to 99.3 % among adults in Uganda (Tables 1 and 2). High 
level of natural immunity was observed in population 
aged between 20 and 40 years.
Of 36 articles reviewed, 22 (61.1  %) articles reported 
sero-prevalence of rubella-specific antibodies among 
pregnant women. The natural immunity of rubella among 
pregnant women was found to range from 52.9  % in 
Benin, Nigeria to 97.9 % in Zaria, Nigeria; implying that 
pregnant women susceptible to rubella infection in these 
countries range from 2.1 to 47.1 % based on different cut 
off points used. Overall, of 7215 pregnant women tested, 
6494 (90 %, 95 % CI; 83.9–85.6) were found to have natu-
ral immunity compared to 6343 (84.8 %, 95 % CI; 89.2–
90.7) of 7480 of general population tested (P  <  0.001). 
Only 12 (33.3  %) articles reported IgM seroprevalence. 
In these articles, IgM seroprevalence was found to range 
from 0.3 % among pregnant women in Mwanza, Tanza-
nia to 45.1 % among children in Jos, Nigeria (Fig. 2).
From few studies which determined seroprevalence 
in urban or in rural settings; the prevalence of rubella-
specific IgG from urban settings ranged from 85.1  % in 
Morocco to 98.2 % in Zaria Nigeria (Tables 1 and 2) while 
in rural population it ranged from 81.5 % in Morocco to 
96.8 % in Maputo, Mozambique. While, of the 22 articles 
which reported rubella-specific seroprevalence rates in 
pregnant women, only 6 articles categorized the study 
participants in relation to residence (rural or urban). No 
significant difference in natural immunity was observed 
between these two settings (Tables 1 and 2).
Regarding the techniques used in these studies all stud-
ies used Enzyme immunoassay (EIA)/enzyme linked 
immunosorbent assay (ELISA) techniques with signifi-
cant variation of the cut off points of these assays. In 
addition, a total of 11 (30.5 %) studies did not specify the 
cut off points used.
Moreover, only two articles assessed rubella virus 
genotypes in Africa. In five countries where rubella 
virus were obtained and genotyped, it was revealed that 
at least three genotypes existed in Africa. Genotype 1E 
exists in Morocco and Sudan; 1G in Uganda, Sudan and 
Cote d’Ivore while genotype 2B exists in South Africa 
and Sudan. Of 15 strains genotyped between 2001 and 
2010, 7 were typed as 1E, 5 as 2B and 3 as 1G genotypes. 
Results indicate that about 20  % of rubella virus strains 
circulating in Africa are non 1E and 2B.
Discussion
Data from different African countries suggests that 
rubella virus is common. In addition these data indicate 
that there is significant number of susceptible women of 
childbearing age signifying the potential risk for giving 
birth to a child with CRS. High seroprevalence rates sug-
gest that rubella virus is constantly circulating in Africa 
continent. Majority of population acquire infections in 
early childhood which accounts for high natural immu-
nity in adolescence and among childbearing women 
[12–14].
The general rubella-specific IgG seroprevalence in 
pre-vaccination era in Africa is comparable with other 
regions in Southern America, India and Europe before 
vaccination [15–19]. However, the level of natural immu-
nity in these studies is lower than the immunity currently 
reported in Europe; this might be due to on-going vacci-
nation programmes in developed countries [20, 21].
Compared to the data from Europe there is a wide vari-
ation of rubella susceptibility in Africa indicating that 
transmission rates differ among regions. This could also 
be attributed to lack of standardized assays as confirmed 
in this review. Data from Europe are before 1970s while 
for Africa are of 2000s. This might possibly indicate 
higher population density variation worldwide.
Generally, no significant difference was observed for 
IgG seroprevalence between urban and rural settings 
in Africa. Similar findings have been observed in South 
America, India and Asia [18, 22].
As documented in other regions; higher IgM sero-
prevalence rate was observed in children and adolescents 
than in adults, with the trend of IgM positivity decreas-
ing with increase in age [14, 23–28]. This indicates high 
transmission rates during childhood emphasizing impor-
tance of vaccination in this age group [29].
There are little information available on genotypes 
of rubella viruses in Africa [30, 31]. Of ten genotypes 
known todate (1A, 1B, 1C, 1D, 1E, 1F, 1G, 2A, 2B and 2C) 
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worldwide, 1E and 2B have been found to have a wide 
geographical distribution [29, 32, 33]. This might not rep-
resent a true picture in Africa because, of 15 strains geno-
typed between 2001 and 2010 in Africa; three (1E, 2B and 
1G) genotypes were detected with 20 % of strains being 
non 1E and 2B [30, 31]. The rare genotype 1G which in 
Africa has been reported in Uganda has been previously 
observed in Israel, Europe and Brazil [34]. This neces-
sitates the need for more phylogenetic studies in Africa 
which will be useful in monitoring genotypes changes in 
future.
Generally this review gives an overview of the current 
situation of rubella virus infection in Africa which may 
be useful for future control strategies. However, a num-
ber of challenges/drawbacks have been observed which 
accounts for limitations in some of the epidemiological 
information. These challenges include: different serologi-
cal assays utilizing different reagents and cut off points 
have been used, making a comparison between the stud-
ies difficult. In addition, some of the articles did not 
document cut-off points for IgG seroprevalence. Most of 
the articles did not assess both IgM and IgG seropreva-
lence at one point in time. This might cause inaccurate 
information about susceptible individuals in some stud-
ies because some of the IgG-negative individuals were 
probably IgM positive. The magnitude of IgM seroposi-
tivity might have been overestimated due to high false 
positive rate of IgM assays. Therefore the data provided 
in this review underscore the need for standardizing sur-
veillance in Africa for rubella virus infection. Majority 
Table 1 Summary of published articles regarding rubella in pregnant women in Africa between 2002 and 2014
NR not reported, NA not applicable
a Mean age
Location/Country Age Sample size IgG+ Cut off points Trimester Study period References
Mwanza, Tanzania 15–44 Urban = 161
Rural = 181
Urban = 146 (90.6 %)
Rural = 171 (94.5 %)
Overall (92.7 %)
10 IU/ml 1 = 13
2 = 171
3 = 133
Nov 2012–May 2013 [28]
Ibadan south west (SW), Nigeria 15–42 273 244 (89.4 %) 10 IU/ml NR July 2010 [36]
Ibadan, Nigeria 15–39 159 109 (68.5 %) 20 IU/ml NR March–Oct 2002 [24]




SW Nigeria 19–44 90 86 (95.5 %) >10 IU/ml NR Oct 2011–May 2012 [38]
Makurdi, Nigeria 18–36 534 NR NR 1 = 534 Feb–July 2007 [26]
SE, Nigeria 19–30 345 329 (95.4 %) NR NR June–Sept 2012 [39]
Benin, Nigeria 16–45 270 143 (52.9 %) ≥10 IU/ml NR NR [27]
Zaria, Nigeria 19–45 Urban = 387
Rural = 43
Urban = 380 (98.2 %)
Rural = 41 (95.3 %)
Overall (97.9 %)
NR NR May 2007–Fe 2008 [40]




Osogbo, Nigeria 15–40 200 175 (87.5 %) >10 IU/ml NR March–June 2011 [42]
W. Sudan 25.7a 231 151 (65.4 %) ≥10 IU/ml NR Aug–Oct 2009 [43]
Khartoum state, Sudan 16–40 80 55 (68.7 %) NR NR June 2012 [44]
Khartoum state, Sudan 16–47 500 465 (93 %) 15 IU/ml NR Nov 2008–March 2009 [45]
Maputo, Mozambique 15–30 Urban = 653
Rural = 321
Urban = 606 (92.8 %)
Rural = 311 (96.8 %)
Overall (94.1 %)
≥15 IU/ml NR Feb–April 2002 [46]
Ouagadougou, Burkina Faso 18–50 100 77 (77 %) NR NR 2006–2008 [47]
Burkina Faso 16–42 Urban = 132
Rural = 209
Urban = 125 (94.7 %)
Rural = 193 (92.3 %)
Overall (93.2 %)
≥10 IU/ml NR Dec 2007–March 2008 [48]
Kenya 15–46 Urban = 470 437 (92.8 %) NR NR June–Dec 2005 [49]
Western cape, S. Africa 15–45 1200 1158 (96.5 %) 0.2 U/ml NR NR [50]
Cameroon 15–40 211 186 (88.1 %) >15 IU/ml NR April–July 2008 [51]
Benin 15–41 Rural = 283 266 (94 %) NR NR July–September 2011 [52]
Total 90 % (52.9–97.9 %)
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of the articles did not indicate whether the participants 
were from rural or urban settings. Therefore it was dif-
ficult to assess the level of immunity on these two popu-
lations in the continent. Of more important, age specific 
seroprevalence and incidence rates were not reported 
in majority of the articles. Therefore, this information is 
not very clear in Africa making the basis of age limit for 
vaccination questionable. Another, information which is 
not clear regarding rubella infection in Africa is seasonal-
ity as none of the articles reviewed investigated on this 
aspect. Lastly, none of the studies assessed the sero-con-
version rate during the course of the pregnancy hence it 
is difficult to estimate the potential risk for CRS in Africa. 
In addition, the data of the magnitude of CRS was not 
documented emphasizing the need for surveillance of 
CRS in Africa [35].
Conclusion
There are few studies in Africa which have investigated 
on molecular epidemiology of rubella virus, there-
fore little is known regarding genotypes of rubella virus 
strains circulating in Africa. In addition very few studies 
have compared epidemiology of rubella virus between 
urban and rural settings. Finally, descriptions of assay/
techniques used were very poor. There is a need to fol-
low WHO guidelines when conducting epidemiological 
research so that data can easily be pooled and help in 
policy formulation.
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Sample size IgG+ Cut off points Study period References
Oyo state, Nigeria Reproductive age 15–45 230 215 (93.4 %) NR 2002 [53]
Vom, Nigeria 20–65 96 87 (90.6 %) NR NR [54]
Kenya Children 4–20 498 398 (79.9 %) NR Feb–June 2005 [12]
Uganda Adults 20–62 311 309 (99.3 %) NR NR [55]
Bangui, Central 
Republic of Africa
Children 1 month–15 395 218 (55.1 %) ≥15 IU/ml July–Dec2008 [13]
Algeria Reproductive age 15–49 834 572 (68.6 %) >10 IU/ml March 2005–March 
2007
[56]
Senegal Reproductive age 15–45 3471 3127 (90 %) >10 IU/ml March–June 2002 [57]
Egypt Women 6–45 Urban = 172
Rural = 426
Urban = 170 (98.8 %)
Rural = 386 (90.6 %)
Overall (96.3 %)
>15 IU/ml NR [58]
Lagos, Nigeria HIV population 18–60 80 59 (73.8 %) NR April 2011–May 2012 [59]
Morocco Reproductive age 15–39 Urban = 502
Rural = 465
Urban = 427 (85.1 %)
Rural = 379 (81.5 %)
Overall (83.3 %)
>8.6 IU/ml 2000 [60]




























































































Fig. 2 IgM seroprevalence in general population in different African 
countries. The highest prevalence is observed in Jos (45.1 %), Nigeria 
among children (1–10 years) and lowest is observed in Tanzania 
(0.3 %) among the pregnant women (15–44 years). Of 2039 tested for 
IgM, 143 (7 %) were positive
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